Treatment of Helicobacter pylori infections: Mitigating factors and prospective natural remedies

African Journal of Biotechnology

Volumn 9, Issue 14, 2010, Pages 2032-2042

  Manyi Loh, Christy E ^a   Clarke, Anna M ^a   Mkwetshana, Noxolo F ^a   Ndip, Roland N ^a,b  

^a UNIVERSITY OF FORT HARE   (South Africa)

^b UNIVERSITY OF BUEA   (Cameroon)

Author keywords

Alternative approaches; Factors affecting treatment; Helicobacter pylori; Natural products; Treatment regimen

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH CITRATE; BISMUTH DERIVATIVE; BISMUTH SALICYLATE; CAPSAICIN; CIMETIDINE; CLARITHROMYCIN; CRANBERRY EXTRACT; ESOMEPRAZOLE; FAMOTIDINE; FURAZOLIDONE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METRONIDAZOLE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; RANITIDINE BISMUTH CITRATE; TETRACYCLINE;

ALTERNATIVE MEDICINE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ATROPHY; BITTER TASTE; CLINICAL EFFECTIVENESS; DEVELOPING COUNTRY; DIARRHEA; DIET THERAPY; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; ERADICATION THERAPY; FECES; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEALTH CARE SYSTEM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HONEY; HUMAN; INFECTION CONTROL; MORTALITY; MOUTH CAVITY; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NAUSEA; PEPTIC ULCER; PHOTOSENSITIVITY; PREVALENCE; REVIEW; RURAL AREA; SANITATION; SIDE EFFECT; SOCIAL STATUS; STOMACH DISEASE; TASTE AVERSION; TOOTH DISCOLORATION; TREND STUDY; VEGETABLE;

HELICOBACTER PYLORI; NEGIBACTERIA;

EID: 77951214302     PISSN: None     EISSN: 16845315     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. Ables AZ, Simon I, Melton ER (2007). Update on Helicobacter pylori Treatment. Am. Fam Physician. 75: 351-358.
2. Adebolu TT (2005). Effect of natural honey on local isolates of diarrheacausing bacteria in South Western Nigeria. Afr. J. Biotechnol. 4(10): 1172-1174.
3. Aiba Y, Suzuki N, Kabir AM, Takagi A, Koga Y (1998). Lactic acidmediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am. J. Gastroenterol. 93: 2097-2101.
4. Alarcón T, Domingo D, Lopez-Bera M (1999). Antibiotic resistance problems with Helicobacter pylori. Int. J. Antimicrob. Agents, 12: 19-26.
5. Ali AT, Chowdhurry MN, Al Humayyd MS (1991). Inhibitory effect of natural honey on Helicobacter pylori. Trop. Gastroenterol.12(3): 139-143
6. Al-jabri AA (2005). Honey, milk and antibiotics. Afr. J. Biotechnol. 4(13): 1580-1587.
7. Aljadi AM, Yusoff KM (2003). Isolation and Identification of Phenolic Acids in Malaysia Honey with Antibacterial Properties. Turk. J. Med. Sci. 33: 229-236.
8. Andersen LP, Colding H, Kristiansen JE (2000). Potentiation of the action of metronidazole on Helicobacter pylori by omeprazole and Bismuth subcitrate. Int. J. Antimicrob. Agents, 14: 231-234.
9. Asrat D, Kassa E, Mengistu Y, Nilsson I, Wadstrom T (2004). Antimicrobial susceptibility pattern of Helicobacter pylori strains isolated from adult dyspeptic patients in Tikur Anbassa University Hospital Addis Ababa. Ethiop. Med. J. 42(2): 79-85
10. Basson NJ, Grobler SR (2008). Antimicrobial activity of two South African honeys produced from indigenous Leucospermum cordifolium and Erica on selected micro-organisms. BMC Complement. Altern. Med. 8: p. 41.
11. Bayerdorffer E, Miehlke S, Mannes GA, Sommer A, Höchter W, Weingart J, Heldwein W, Klann H, Simon T, Schmitt W, Bästlein E, Eimiller A, Hatz R, Lehn N, Dirschedl P, Stolte M (1995). Doubleblind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology, 108: 1412-1417.
12. Bazzoli F, Zargari RM, Fossi SP, Rida A, Roda E (1993). Efficacy and tolerability of a short term, low-dose triple therapy for the eradication of H. pylori. Gastroenterology, 104: A140.
13. Bland MV, Ismail S, Heinemann JA, Keenan J (2004). The Action of Bismuth against Helicobacter pylori Mimics but Is Not Caused by Intracellular Iron Deprivation. Antimicrob. Agents Chemother. 48(6): 1983-1988.
14. Blaser MJ (1999). Hypothesis: the changing relationships of Helicobacter pylori and Humans: implications for health and diseases. J. Infect. Dis.179: 1523-1530.
15. Bergonzelli GE, Blum S, Brüssow H, Corthésy-Theulaz I (2005). Probiotics as a treatment strategy for gastrointestinal diseases? Dig. Dis Sci. 72(1): 57-68.
16. Boyanova L, Stancheva I, Spassova Z, Katzarov N, Mitov I, Koumanova R (2000). Antimicrobial resistance; primary and combined resistance to four antimicrobial agents in Helicobacter pylori in Sofia, Bulgaria. J. Med. Microbiol. 49: 415-418.
17. Burger O, Ofek I, Tabak M, Weiss E, Sharon N, Neeman I (2000). A high molecular mass constituent of cranberry juice inhibits Helicobacter pylori adhesion to human gastric mucus. FEMS Immunol. Med. Microbiol. 29: 295-301.
18. Bury-Moné S, Skouloubris S, Dauga C, Thiberge JM, Dailidiene D, Berg DE, Labigne A, De reuse H (2003). Presence of active aliphatic amidases in Helicobacter species able to colonise the stomach. Infect. Immun. 71(10): 5613-5622.
19. Bytzer P, O'Morain C (2005). Treatment of Helicobacter pylori. Helicobacter.10: 40-45.
20. Calafatti AS, Santos A, Da Silva CMF, Deguer M, Carvalho AF, Mendes FD, Ferraz JGP, Bento AP, Pereira AA, Piovesana H, De Nucci G, Lerner F, Pedrazolli J Jr (2000). Transfer of metronidazole to gastric juice: impact of Helicobacter pylori and omeprazole. Scand. J. Gastroenterol. 35: 699-704.
21. Calvet X, Carod C, Gene E (2000). Re. peppers at treatment for Helicobacter pylori infection. Am. J. Gastroenterol. 95(3): 820-821.
22. Cats A, Kuipers EJ, Bosschaert MA, Pot RG, Vandenbrouke-Grauls CM, Kusters JG (2003). Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pyloricolonized subjects. Aliment. Pharmacol.Ther. 17:429-35.
23. Cichewicz RH, Thorpe PA (1996). The antimicrobial properties of chile peppers (Capsicum species) and their uses in Mayan medicine. J. Ethnopharmacol. 52: 61-70.
24. Coconnier MH, Lievin V, Hemery E, Servin AL (1998). Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl. Environ. Microbiol. 64: 4544-4573.
25. De Boer WA, Driessen WM, Janz AR, Tytgat GN (1995). Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet, 345: 817-20.
26. De Boer WA, Tytgat GN (2000). Treatment of Helicobacter pylori. Br Med. J. 320:31-4
27. De Francisco V, Margiotta M, Zullo A, Hassan C, Giorgio F, Burattini O, Stoppino G, Cea U, Pace A, Zotti M, Morini S, Panella C, Ierardi E (2007). Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J. Antimicrob. Chemother. 59: 783-785.
28. Deltenre MA (1997). Economics of Helicobacter pylori eradication therapy. Eur. J. Gastroenterol. Hepatol. 9(Suppl 1): S27-S29.
29. Destura RV, Labio ED, Barrett LJ, Alcantara CS, Gloria VI, Daez MLO, Guerrant RL (2004). Laboratory diagnosis and susceptibility profile of Helicobacter pylori infection in the Philippines. Ann. Clin. Microbiol. Antimicrob. 3: 25-30.
30. Dube C, Tanih NF, Ndip RN (2009a). Helicobacter pylori in water sources: A global environmental health concern. Rev. Environ. Health, 24(1): 1-14.
31. Dube C, Nkosi TC, Clarke AM, Mkwetshana N, Green E, Ndip, RN (2009b). Helicobacter pylori in an asymptomatic population of Eastern Cape Province, South Africa: Public health implication. Rev. Environ. Health, 24(3): 249-255.
32. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC (1997). The stability of amoxicillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J. Antimicrob. Chemother. 39: 5-12.
33. Ernst PB, Gold BD (2000). The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastro duodenal ulcer and gastric cancer. Ann. Rev. Microbiol. 54: 615-640.
34. Farthing MJG (1998). Helicobacter pylori infection: an overview. Br. Med. Bull. 54(1): 1-6.
35. Feldman RA (2001). Epidemiologic observations and open questions about disease and infection caused by Helicobacter pylori. In Achtman M and Suerbaum S(eds) Helicobacter pylori:molecular and cellular biology. Wymondham,United Kingdom, Horizon Scientific press, pp. 29-51.
36. Ford AC, Malfertheiner P, Giguère M, Santana J, Khan M, Oayyedi P (2008). Adverse events with bismuth salts for Helicobacter pylori eradication: Systematic review and meta-analysis. World Gastroenterol. 14(48): 7361-7370.
37. Franceschi F, Cazzato A, Nista EC, Scarpellini E, Roccarina D, Gigante G, Gasbarrini G Gasbarrini A (2005). Role of probiotics in Patients with Helicobacter pylori infection. Helicobacter. 2(2): 59-63.
38. Fuller R(1991). Probiotics in human medicine. Gut. 32: 439-442.
39. Gendull JH, Friedman SL, McQuaid KR (2003). Identification of Helicobacter pylori.In:Current diagnosis and treatment in gastroenterology. Gendull JH, Friedman SL, and McQuaid K R.(eds). Google books. pp. 328-335.
40. Gheldof N, Wang XH, Engeseth NJ (2002). Identification and quantification of antioxidant components of honey from various floral source. J. Agric. Food Chem. 50: 5870-5877.
41. Gill HS (2003). Probiotics to enhance anti-infective defences in the gastrointestinal tract. Best Pract Res. Clin. Gastroenterol. 17: 755-73.
42. Goddard AF, Spiller RC(1996). Effect of omeprazole on gastric juice viscosity. Aliment. Pharmacol. Ther. 10: 105-109.
43. Gómez-Caravaca AM, Gómez-Romero M, Arráez-Román D, Segura-Carreto A, Fernández-Gutiérrez A (2006). Advances in the analysis of phenolic compounds in products derived from bees. J. Pharm. Biomed. Anal. 41: 1220-1234.
44. Goodwin CS, Marshall BJ, Blincow ED, Wilson DH, Blackbourn S (1988). Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of bismuth subcitrate:clinical and in vitro studies. J. Clin. Pathol. 41: 207-210.
45. Gottenland M, Brunser O, Cruchet S (2006). Systematic Review: Are probiotics useful in controlling Gastric Colonization By Helicobacter pylori? Aliment. Pharmacol. Ther. 23(8): 1077-1086.
46. Gramley WA, Asghar A, Frilersan F, Henri JR, Powel M (1999). Detection of H. pylori DNA in faecal samples from infected individuals. J. Clin. Microbiol. 37: 2236-2240.
47. Gustarson LE, Kaiser JF, Edmonds AL (1995). Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob. Agents Chemother. 39: 2078-2083.
48. Haller D, Bode C, Hammes WP, Pfeiffer AM, Schiffrin EJ, Blum S (2000). Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut. 47: 79-87.
49. Hardin FJ, Wright RA (2002). Helicobacter pylori: review and update. Arch. Hosp. Physician. 38(5): 23-31.
50. Harris A (1998). Current regimens for treatment of Helicobacter pylori infection. Br. Med. Bull. 54(1): 195-205.
51. Harris A, Misiewicz JJ (2002). Management of Helicobacter pylori infection. In: ABC of upper gastrointestinal tract. Logan RDH, Harris A, Misiewicz JJ, Baron JH (eds). BMJ books London. pp. 22-24.
52. Hsu PI, Wu DC, Chen A, Peng NJ, Tseng HH, Tsay FW, Lo GH, Lu CY, Yu FJ, Lai KH (2008). Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures. Eur. J. Clin. Invest. 38(6): 404-409.
53. Huynh HQ, Couper RTL, Tran CD, Moore L, Kelso R, Butler RN (2004). N-acetylcysteine, a novel treatment for Helicobacter pylori Infection. Dig. Dis Sci. 49(11/12): 1853-1861.
54. Iurlina MO, Fritz R (2005). Characterization of micro-organisms in Argentinean honeys from different sources. Int. J. Food Microbiol.105: 297-304.
55. Jones NL, Shabib S, Sherman PM (1997). Capsaicin as an inhibitor of growth of the gastric pathogen Helicobacter pylori. FEMS Microbiol. Letters.146:223-227.
56. Kang JY, Yeoh KG, Chia HP, Lee HP, Chia YW, Guan R, Yap I (1995). Chili protective factor against peptic ulcer? Dig. Dis. Sci. 40: 576-579.
57. Kim JJ, Kim JG, Kwon DH (2003). Mixed-infection of antibiotic susceptible and resistant Helicobacter pylori isolates in a single patient and under estimation of antimicrobial susceptibility testing. Helicobacter, 8(3): 202-206.
58. Kim TS, Hur JW, Yu MA, Cheigh CI, Kim KN, Hwang JK, Pyun YR (2003). Antagonism of Helicobacter pylori bacteriocins of lactic acid bacteria. J. Food Prot. 66:3-12
59. Kwon DH, Kim JJ, Lee M, Yamaoka Y, Kato M, Osato MS, EL-Zaatari FAK, Graham DY (2000). Isolation and characterization of tetracycline-resistant clinical isolates of Helicobacter pylori. Antimicrob. Agents. Chemother. 44: 3203-3205.
60. Laine L, Estrada R, Trujillo M, Emami S (1997). Randomized comparison of ranitidine bismuth citrate based triple therapies for Helicobacter pylori. Am. J. Gastroenterol. 12: 2213-2215.
61. Larsen A, Martiny M, Stoltenberg M, Danscher G, Rung BY (2003). Gastrointestinal and systemic uptake of bismuth in mice after oral exposure. Pharmacol. Toxicol. 93: 82-90.
62. Lee SP (1991).The mode of action of colloidal bismuth subcitrate. Sc and J. Gastroenterol. 26(suppl.185): 1-6.
63. Lee YC, Liou JM, Wu MS, Wu CY, Lin JT (2008). Eradication of Helicobacter pylori to prevent gastroduodenal diseases: Hitting more than one bird with the same stone. Ther. Adv. Gastroenterol. 1(2): 111-120.
64. Leodotler A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P (2001). A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pyloriassociated gastric or duodenal ulcer. Aliment. Pharmacol. Ther.15: 1949-1958.
65. Lesbros-Pantoflickova D, Corthésy-theulaz I, Blum AL (2007). Helicobacter pylori and Probiotics. J. Nutr. 137: 812S-818S.
66. Li CQ, Pignatelli B, Ohshima H (2001). Increased oxidative and nitrative stress in human stomach associated with cag A+Helicobacter pylori infection and inflammation. Dig. Dis. Sci. 46: 836-844.
67. Lind T, Mégraud F, Unge P, Bayerdorffer E, O'Morain C, Spiller R, Veldhuyzen Van Zanten S, Bardhan KD, Hellblom M, Wrangstadh M, Zeijlon L, Cederberg C (1999). The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology, 116: 248-53.
68. Lorca GL, Wadstrom T, Valdez GF, Lyungh A (2001). Lactobacillus acidophilus autolysins inhibit Helicobacter pylori in vitro. Curr. Microbiol. 42: 39-44.
69. Ma JL, You WC, Gail MH, Zhang L, Blot WJ, Chang YS, Jiang J, Liu WD, Hu YR, Brown LM, Xu GW, Fraumeni JF Jr (1998). Helicobacter pylori infection and mode of transmission in a population at high risk of stomach cancer. Int. J. Epidemiol. 27: 570-573.
70. Mahady GB, Pendland S (2000). Garlic and Helicobacter pylori. Am. J. Gastroenterol. 95(1): p. 209.
71. Malekzadeh R, Mohamadnejad M, Siavoshi F, Massarat S (2004). Treatment of Helicobacter pylori infection in Iran: Low efficacy of recommended Western regimens. Arch. Iran Med. 7(1): 1-8.
72. Malfertheiner P, Bayerdorffer E, Diete U, Gil J, Lind T, Misiuna P, O'Morain C, Sipponen P, Spiller RC, Stasiewicz J, Treichel HC, Ujszazy L, Unge P, Van Zanten SJOV, Zeijlon L (1999). The GUMACH study: the effect of 1 week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment. Pharmacol. Ther. 13: 703-712.
73. Malfertheiner P, Mégraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G (2002). Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment. pharmacol. Ther. 16: 167-180.
74. Megraud F, Lamouliatte H (2003). Review article: the treatment of refractory Helicobacter pylori infection. Aliment. Pharmacol. Ther. 17: 1333-1343.
75. Megraud F (2004). H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 53: 1374-1384.
76. Meurer L, Bower D (2002). Management of Helicobacter pylori Infection. Am. Fam. Physician 65(7): 1327-1336, 1339.
77. Michetti P, Dorta G, Wiesel PH, Brassart D, Verdu E, Herranz M, Felley C. Porta N, Rouver M, Blum AL, Corthesy-Theulaz I (1999). Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Dig. 60: 203-9.
78. Midolo PD, Lambert JR, Hull R, Luo F, Grayson ML (1995). In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J. Appl. Bacteriol. 79: 475-479.
79. Midolo PD, Lambert T, kerr TG, Tee W (1999). In vitro synergy between ranitidine bismuth citrate and tetracycline or clarithromycin against resistant strains of Helicobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis. 18: 832-834.
80. Módena JLP, Acrani GO, Micas AFD, de Castro M, da Silveira WD, M-dena JLP, de Oliveira RB, Brocchi M (2007). Correlation between Helicobacter pylori Infection, gastric diseases and life habits among patients treated at a University Hospital in Southern Brazil. Brazilian J. Infect. Dis. 11(1): 89-95.
81. Molina-Torres J, Garcia-chavez A, Ramirez-chavez E (1999). Antimicrobial properties of alkamides present in flavouring plants traditionally used in Masoamerica: affinin and capsaicin. J. Ethnopharmacol. 64: 241-248.
82. Mollison LC, Stingemore N, Wake RA, Cullen DJ, McGechie DB (2000). Antibiotic resistance in Helicobacter pylori. Med. J. Aust. 173: 521-523.
83. Mukai T, Asasaka T, Sato E, Mori K, Matsumoto M, Ohori H (2002). Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol. Med. Microbiol. 32: 105-110.
84. Nakao M, Malfertheiner P (1998). Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter, 3: 21-27.
85. Namias N (2003). Honey in the management of infections. Surg. Infect. 4(2): 219-226.
86. Nam H, Ha M, Bae O, Lee Y (2002). Effect of Wiessella confusa strain PL9001 on the adherence and growth of Helicobacter pylori. Appl. Environ. Microbiol. 68: 4642-4645.
87. Ndip RN, Malange AE, Akoachere JFT, Mackay WG, Titanji VPK, Weaver LT (2004). Helicobacter pylori antigens in the faeces of asymptomatic children in the Buea and Limbe health districts of Cameroon: a pilot study. Trop. Med. Int. Health, 9(9): 1036-1040.
88. Ndip RN, Dilonga HM, Ndip LM, Akoachere JFT, Nkuo-Akenji T (2005). Pseudomonas aeruginosa isolates recovered from clinical and environmental samples in Buea, Cameroon: current status on biotyping and antibiogram. Trop. Med. Int. Health, 10(1): 74-81.
89. Ndip RN, Malange Tarkang AE, Mbullah SM, Luma HN, Malongue A, Ndip LM, Nyongbela K, Wirmum C, Efange SMN (2007a). Invitro anti-Helicobacter pylori activity of extracts of medicinal plants from North West Cameroon. J. Ethnopharmacol. 114: 452-457.
90. Ndip R, Malange Takang AE, Echakachi CM, Malongue A, Akoachere JFTK, Ndip LM, Luma HN (2007b). In vitro antimicrobial activity of selected honeys on clinical isolates of Helicobacter pylori. Afr. Health Sci. 7(4): 228-231.
91. Ndip RN, Takang MEA, Ojongokpoko AEJ, Luma HN, Malongue A, Akoachere KTJ, Ndip ML, MacMillan M, Weaver TL (2008a). Helicobacter pylori isolates recovered from gastric biopsies of patients with gastro-duodenal pathologies in Cameroon: Current status of antibiogram. Trop. Med. Int. Health, 13(6): 848-854.
92. Ndip RN, Ajonglefac AN, Mbullah SM, Tanih NF, Akoachere JFK, Ndip LM, Luma HN, Wirmum C, Ngwa F, Efange SMN (2008b). In vitro anti-Helicobacter pylori activity of Lycopodium cernuum (Linn) Pic. Serm. Afr. J. Biotechnol. 7: 3989-3994.
93. Nguyen LT, Uchida T, Tsukamoto Y, Trinh TD, Ta L, Ho DQD, Matsuhisa T, Uchida M, Takayama A, Hijiya N, Okimoto T, Kodama M, Murakami K, Fujioka T, Moriyama M (2009). Evaluation of Rapid Urine Test for the Detection of Helicobacter pylori Infection in the Vietnamese population. Dig. Dis. Sci. Springer: DOI 10.1007/s10620-009-0720-9.
94. Oboh G (2005). Effect of blanching on the antioxidant property of some Tropical green leafy vegetables Lebensm-Wiss. Food Sci. Technol. 38(5): 513-517.
95. Osato MS, Reddy SG, Graham DY (1999). Osmotic effect of honey on growth and viability of Helicobacter pylori. Dig. Dis. Sci. 44(3): 462-464.
96. Parkman HP, Urbain JL, Knight LC, Brown KL, Trate DM, Miller MA, Maurer A, Fisher R (1998). Effect of gastric acid suppressants on human gastric motility. Gut. 42: 243-50.
97. Pedrazzoli J, Calafatti SA, Ortiz RA, Dias FE, Deguer M, Mendes FD, Bento AP, Pereira AA, Piovesana H, Ferraz JG, Lerner F, de Nucci G (2001). Transfer of clarithromycin to gastric juice is enhanced by omeprazole in Helicobacter pylori-infected individuals. Scand. J. Gastroenterol. 36: 1248-1253.
98. Peitz U, Sulliga M, Wolle K, Leodolter A, Von Arnim U, Kahl S, Stolte M, Börsch G, Labenz J, Malfertheiner P (2002). High rate of posttherapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two secondline therapies in a randomized study. Aliment. Pharmacol. Ther.16: 315324.
99. Phull PS, Green CI, Jacyna MR (1995). A radical view of the stomach: The role of Oxygen-derived free radical and anti-oxidants in gastroduodenal diseases. Eur. J. Gastroenterol. Hepatol. 7: 265-274
100. Pinchuk IV, Bressolier P, Verneuil B, Fenet B, Sorokulova IB, Megraud F, Urdaci MC (2001). In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics. Antimicrob. Agents. Chemother. 45: 3156-3161.
101. Ricci V, Zarrilli R, Romano M (2002). Voyage of Helicobacter pylori in human stomach: odyssey of a bacterium. Dig. Liver Dis. 34: 2-8.
102. Richter JE (2001). H. pylori: the bug is not all bad. Gut. 49: 319-320.
103. Rolfe RD (2000). The role of probiotic cultures in the control of gastrointestinal health. J. Nutr.130: S396-402.
104. Romano M, Cuomo A (2004). Eradication of Helicobacter pylori: A clinical update. Medscape Gen. Med. Gastroenterol. 6(1): p. 19.
105. Sandha GS, LeBlanc R, Sander JO, Van Zanten V, Sitland TD, Agocs L, Burford N, Best L, Mahoney D, Hoffman P, Leddin DJ (1998). Chemical structure of Bismuth compound determines their gastric ulcer healing efficacy and Anti-Helicobacter pylori activity. Dig. Dis. Sci. 43(12): 2727-2732.
106. Sato T, Miyata G (2000). The nutraceutical benefit, Part 111: Honey. Nutr.16:468-469.
107. Savarino V, Mansi C, Mele MR, Bisso G, Mela GS, Saggioro A, Caroli M, Vigneri S, Termini R, Olivieri A, Tosatto R, Celle C (1997). A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics. Aliment. Pharmacol. Ther.11: 323-329.
108. Scarpignato C (2004). Towards the ideal regimen for Helicobacter pylori eradication: the search continues. Dig. Liver Dis. 36: 243-247.
109. Scott D, Weeks D, Melchers K, Sachs G (1998). The life and death of Helicobacter pylori. Gut. 43: 56-60.
110. Sgouras D, Maragkoudakis P, Petraki K, Martinez-Gonzalez B, Eriotou E, Michopoulos S, Kalantzopoulos G, Tsakalidou E, Mentis A (2004). In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei Shirota. Appl. Environ. Microbiol. 70: 518-526.
111. Sherif M, Mohran Z, Fathy H, Rockabrand DM, Rozmajzl PJ, Frenck RW (2004). Universal high-level primary metronidazole resistance in Helicobacter pylori isolated from children in Egypt. J. Clin. Microbiol. 42(10): 4832-4834.
112. Sivam GP (2001). Protection against Helicobacter pylori and other bacterial infection by garlic. J. Nutr.131(3s): 1106S-1108S.
113. Somal NA, Coley KE, Molan PC, Hanock BM (1994). Susceptibility of Helicobacter pylori to the antibacterial activity of manuka honey. J. Roy. Soc.Med.87:9-12.
114. Sox TE, Olson CA (1989). Binding and killing of bacteria by bismuth subsalicylate. Antimicrob. Agents Chemother. 33: 2075-2082.
115. Stamatis G, Kyriazopoulos P, Golegou S, Basayiannis A, Skaltsas S, Skaltsa H (2003). In vitro anti -Helicobacter pylori activity of Greek herbal medicines. J. Ethnopharmacol. 88: 175-179.
116. Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, McLaughlin PW, Rodriguez MA, Romaguera JE, Sarris AH, Younes A, Luthra R, manning JT, Johnson CM, Lahoti S, Shen Y, Lee JE, Winn RJ, Genta RM, Graham DY, Cabanillas FF (1999). Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. Ann. Int. Med.131: 88-95.
117. Stenström B, Mendis A, Marshall B (2008). Helicobacter pylori: the latest in diagnosis and treatment. Aust. Fam. Physician. 37(8): 608-612.
118. Tanih NF, Clarke AM, Mkwetshana N, Green E, Ndip LM, Ndip RN (2008). Helicobacter pylori infection in Africa: Pathology and microbiological diagnosis. Afr. J. Biotechnol. 7(25): 4653-4662.
119. Tanih NF, Dube C, Green E, Mkwetshana N, Clarke AM, Ndip LM, Ndip RN (2009a). An African perspective on Helicobacter pylori: prevalence of human infection drug resistance, and alternative approaches to treatment. Ann. Trop. Med. Parasitol. 103(3): 189-204.
120. Tanih NF, Okeleye BI, Naido N, Clarke AM, Mkweshana N, Green E, Ndip LM, Ndip RN (2009b). Marked susceptibility of South African Helicobacter pylori strains to ciprofloxacin and amoxicillin: Clinical implication. S. Afr. Med. J. (In Press)
121. Temaru E, Simura S, Amano K, Karasawa T (2007). Antibacterial Activity of Honey from Stingless Honeybees (Hymenoptera; Apidae; Meliponinae). Pol. J. Microbiol. 56 (4): 281-285.
122. Thomas JE, Dale A, Bunn JE, Harding M, Coward W, Cole TJ, Weaver LT (2004). Early Helicobacter pylori colonization: the association with growth faltering in The Gambia. Arch. Dis. Child. 89(12): 1149-1154.
123. Tiwari SK, Khan AA, Ahmed KS, Ahmed I, Kauser F, Hussain MA, Ali SM, Alvi A (2005). Rapid diagnosis of Helicobacter pylori infection in dyspeptic patients using salivary secretion: a non-invasive approach. Singapore Med. J. 46(5): p. 224.
124. Tokunaga Y, Shirahase H, Hoppou T, Kitaoka A, Tokuka A, Ohsumi K (2000). Density of Helicobacter pylori infection evaluated semi quantitatively in gastric cancer. J. Clin. Gastroenterol. 31: 217-221.
125. Ushiyama A, Tanaka K, Aiba Y, Siba T, Takagi A, Mine T, Koga, Y (2003). Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin-resistant Helicobacter pylori infection. J. Gastroenterol. Hepatol. 18(8): 986-891.
126. Vaira D, Malfertheiner P, Mégraud F, Axon AT, Deltenre M, Gasbarrini G, O'Morain C, Pajares Garcia JM, Quina M, Tytgat GN (2000). Non invasive antigen-based assay for assessing Helicobacter pylori eradication: a European multicentre study. The European Helicobacter pylori HpSA Study Group. Am. J. Gastroenterol. 95(4): 925-929.
127. Vitini E, Alvarez S, Medina M, Medici M, de Budeguer MW, Perdigon G (2000). Gut mucosal immunostimulation by lactic acid bacteria. Biocell, 24: 223-232.
128. Weston R (2000).The contribution of catalase and other natural products to the antibacterial activity of honey: a review. Food Chem. 71: 235-239.
129. Wong BCY, Chang FY, Abid S, Abbas Z, Lin CBR, Rensburg CV, Chen PC, Schneider H, Simjee AE, Hamid SS, Seebaran A, Zhang J, Destefano M (2002). Triple therapy with clarithromycin, omeprazole and amoxiciilin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. Aliment. Pharmacol. Ther.14: 1529-1535.
130. Wotherspoon MC (1998). Helicobacter pylori infection and gastric lymphoma. Br. Med. Bull. 54(1): 79-85.
131. Wu J, Sung J (1999). Treatment of Helicobacter Pylori infection. Hong Kong Med. J. 5 (2): 145-149.
132. Yao L, Jiang Y, Singanusong R, Datta N, Raymont K (2004). Phenolic acids and abscissic acid in Australian Eucalyptus honeys and their potential for floral authentication. Food Chem. 84: 167-177.
133. Zanten SJ, Bradette M, Farley A, Leddin D, Lind T, Unge P, Bayerdorffer E, Spiller RC, O'Morain C, Sipponen P, Wrangstadh M, Zeijlon L, Sinalair P (1999).The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment. Pharmacol. Ther.13: 289-295.
134. Zeyrek FY, Oguz E (2005). In vitro activity of capsaicin against Helicobacter pylori. Ann. Microbiol. 55(2): 125-127.
135. Zhang L, Ma J, Pan K, Go VLW, Chen J, You WC (2005). Efficacy of Cranberry juice on Helicobacter pylori infection: a double-blind, randomized placebo-controlled trial. Helicobacter, 10(2): 139-145.